New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
09:18 EDTPCYC, JNJPharmacyclics price target raised to $80 from $65 at Roth Capital
Roth Capital expects Pharmacyclics (PCYC) to benefit from the launch of its partnership with Johnson & Johnson (JNJ), and its plans to expand its ibrutinib drug into the treatment of new indications. The firm maintains a Buy rating on the stock.
News For PCYC;JNJ From The Last 14 Days
Check below for free stories on PCYC;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2014
14:11 EDTPCYCPharmacyclics weakness on safety issues overdone, says Deutsche Bank
Subscribe for More Information
August 18, 2014
16:08 EDTPCYCPharmacyclics names Shawn Cline Tomasello as Chief Commercial Officer
Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4B in revenue. Prior to joining Celgene, Cline Tomasello was the National Director of Hematology for Rituxan at Genentech, where she was responsible for over $1.7B in revenue.
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 12, 2014
09:35 EDTJNJActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
August 8, 2014
09:01 EDTJNJJohnson & Johnson remains undervalued, says Cowen
Subscribe for More Information
08:17 EDTPCYCPharmacyclics announces Jesse McGreivy to step down from Chief Medical Officer
Subscribe for More Information
August 6, 2014
06:21 EDTJNJPiper Jaffray to hold a summit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use